- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 7, Issue 4, 2001
Current Pharmaceutical Design - Volume 7, Issue 4, 2001
Volume 7, Issue 4, 2001
-
-
The Nuclear Receptors FXR and LX alpha Potential Targets for the Development of Drugs Affecting Lipid Metabolism and Neoplastic Diseases
Authors: E.J. Niesor, J. Flach, I. Lopes-Antoni, A. Perez and C.L. BentzenThe orphan nuclear receptors FXR and LXR alpha have become challenging targets for the discovery of new therapeutic agents. Bile acids and hydroxysterol intermediates are the respective natural ligands of these two structurally and functionally closely related receptors. Both FXR and LXR alpha are thought to play a major role in the control of cholesterol catabolism by regulating the expression of cholesterol 7alpha-hy Read More
-
-
-
Endurance Exercise Training and Reproductive Endocrine Dysfunction in Men Alterations in the Hypothalamic-Pituitary-Testicular Axis
By A.C. HackneyResearch indicates that endurance exercise training has significant effects upon the reproductive endocrine system of humans. Until recently, this effect was thought to be limited primarily to women. However, a growing body of evidence demonstrates that the male reproductive endocrine system is also effected. Specifically, the circulating hormonal levels of testosterone are found to be at low concentrations and, the hypot Read More
-
-
-
Pharmacological Interference with Transcriptional Control of Osteoblasts A Possible Role for Leptin and Fatty Acids in Maintaining Bone Strength and Body Lean Mass
Authors: J.O. Gordeladze, J.E. Reseland and C.A. DrevonOsteoblasts pass through a sequence of events controlled by hormones and transcriptional factors ensuring proper development of phenotype and functional properties until the osteoblast enter the osteocyte phenotype and/or undergo apo-ptosis. During its life cycle, the osteoblasts proliferate, deposit matrix proteins and mineralize it until they turn into osteocytes believed to constitute a mechanosensor mesh giving feed-back t Read More
-
-
-
Proteomics as a Tool in the Pharmaceutical Drug Design Process
Authors: M. Yosida, J.A. Loo and R.A. LepleyProteomics is a technology platform that is gaining widespread use in drug discovery and drug development programs. Defined as the protein complement of the genome, the proteome is a varied and dynamic repertoire of molecules that in many ways dictates the functional form that is taken by the genome. The importance of proteomics is a direct consequence of the central role that proteins play in establishing the biol Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
